Jane Street’s Verve Therapeutics VERV Stock Holding History

Jane Street’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,400	Closed	-$187K	–	10139
2023 Q4	$187K	Buy	+13,400	New	+$166K	﹤0.01%	8266
2023 Q3	–	Sell	-20,000	Closed	-$375K	–	9459
2023 Q2	$375K	Sell	20,000 -15,200	-43%	-$253K	﹤0.01%	6770
2023 Q1	$508K	Buy	+35,200	New	+$689K	﹤0.01%	6289
2022 Q4	–	Sell	-25,500	Closed	-$876K	–	10209
2022 Q3	$876K	Buy	+25,500	New	+$814K	﹤0.01%	5648

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Jane Street's VERV Position: Q3 2025 in Review

Jane Street sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 198,657 shares — an estimated $2.23M sold.

Jane Street first reported a position in VERV in Q2 2021 and held it in 14 quarters. The position peaked at $3.79M in Q4 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Jane Street reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Jane Street sold 198,657 Verve Therapeutics shares in Q3 2025, an estimated $2.23M.
Jane Street first reported a position in Verve Therapeutics in Q2 2021 and held it in 14 quarters.
Jane Street's Verve Therapeutics position peaked at $3.79M in Q4 2023.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.